For patients with previously untreated mantle cell lymphoma, MRD positivity after induction and consolidation treatments was associated with worse outcomes for both progression-free survival (PFS) and overall survival (OS) in a systematic review and meta-analysis published in January in the Journal of Cancer.
The authors, from the National Cancer Center in Beijing, China, identified 10 randomized controlled trials or patient cohort studies that reported an association between MRD and survival outcomes. All 10 studies reported MRD-related PFS; 6 reported MRD-related OS. Six studies included patients who were eligible for autologous stem cell transplantation (ASCT). The included studies that used multiple induction, maintenance, and post-consolidation regimens. In 9 studies, MRD was assessed after the completion of induction treatment. Four studies reported MRD status and related survival outcomes after ASCT or during maintenance. The authors identified no significant publication bias.
Compared with MRD-negative status, post-induction MRD positivity was associated with worse PFS (hazard ratio 1.44) and OS (hazard ratio 1.30). Post consolidation, MRD positivity predicted both shorter PFS (hazard ratio 1.84) and OS (hazard ratio 2.38) compared with MRD negativity.
“MRD-based treatment strategies should be further explored in clinical trials and real-world practice,” the authors conclude.
– Zhou Y, Chen H, Tao Y, et al. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. J Cancer. 2021; 12(2): 553-561. doi: 10.7150/jca.51959